Lead Product(s) : Oxypurinol
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
XORTX Announces Update for Discussion with the FDA
Details : XRx-026 program is a proprietary formulation of oxypurinol, which is being developed to treat patients suffering from gout.
Product Name : XRx-026
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2025
Lead Product(s) : Oxypurinol
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxypurinol
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
XORTX Commences Gout Program NDA Discussions with the FDA
Details : XRx-026 program is a proprietary formulation of oxypurinol, which is being developed to treat patients suffering from gout.
Product Name : XRx-026
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2025
Lead Product(s) : Oxypurinol
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegadricase,ImmTOR
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : $705.0 million
Deal Type : Licensing Agreement
Details : Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory g...
Product Name : SEL-212
Product Type : Enzyme
Upfront Cash : $75.0 million
October 31, 2023
Lead Product(s) : Pegadricase,ImmTOR
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : $705.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pegadricase,SEL-110
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
Details : SEL-212 (combination of ImmTOR immune tolerance platform and pegadricase) is designed to reduce serum urate levels in people with chronic refractory gout, potentially reducing harmful tissue urate deposits which causes debilitating gout flares and joint ...
Product Name : SEL-212
Product Type : Enzyme
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : Pegadricase,SEL-110
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Cartilagenous Tissue
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
Details : Ocugen’s proposed control and overall design for the Phase 3 study of NeoCart®, a regenerative cell therapy for the repair of full-thickness lesions of the knee cartilage in adults.
Product Name : NeoCart
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 16, 2022
Lead Product(s) : Autologous Cartilagenous Tissue
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Innovent Biologics
Deal Size : $95.5 million
Deal Type : Collaboration
Details : LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.
Product Name : LC350189
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
December 14, 2022
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Innovent Biologics
Deal Size : $95.5 million
Deal Type : Collaboration
Lead Product(s) : Pegadricase
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Selecta Biosciences
Deal Size : $4.0 million
Deal Type : Licensing Agreement
Details :
Product Name : SEL-212
Product Type : Enzyme
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : Pegadricase
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Selecta Biosciences
Deal Size : $4.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pegadricase
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Sobi and Selecta Biosciences Announce Topline Data of SEL-212 From the Phase 2 COMPARE Study
Details : Patients with tophi showed a substantially higher overall response rate for SEL-212 versus pegloticase and a statistically significant overall reduction in mean SUA levels for SEL-212 versus pegloticase.
Product Name : SEL-212
Product Type : Enzyme
Upfront Cash : Inapplicable
September 30, 2020
Lead Product(s) : Pegadricase
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Swedish Orphan Biovitrum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegadricase
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Selecta Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The phase 3 DISSOLVE clinical programme a randomized double-blind, placebo-controlled study in which SEL-212 will be evaluated at two doses of ImmTOR, and one dose of pegadricase in both studies.
Product Name : SEL-212
Product Type : Enzyme
Upfront Cash : Inapplicable
September 23, 2020
Lead Product(s) : Pegadricase
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Selecta Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eisai and FUJI YAKUHIN Conclude License Agreement
Details : Under this agreement, Eisai will proceed with the development of dotinurad in China.
Product Name : Urece
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 25, 2020
Lead Product(s) : Dotinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement